Ascendis Pharma A/S banner

Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 216.95 USD -1.65% Market Closed
Market Cap: $13.4B

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 299.54 USD with a low forecast of 257.55 USD and a high forecast of 359.1 USD.

Lowest
Price Target
257.55 USD
19% Upside
Average
Price Target
299.54 USD
38% Upside
Highest
Price Target
359.1 USD
66% Upside
Ascendis Pharma A/S Competitors:
Price Targets
DXPE
DXP Enterprises Inc
6% Upside
RYI
Ryerson Holding Corp
50% Upside
OFIX
Orthofix Medical Inc
53% Upside
SUPN
Supernus Pharmaceuticals Inc
30% Upside
ARDX
Ardelyx Inc
196% Upside

Revenue
Forecast

35% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
35% / Year
Past Growth
53% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

For the last 12 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 35%. The projected CAGR for the next 3 years is 53%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
299.54 USD

According to Wall Street analysts, the average 1-year price target for ASND is 299.54 USD with a low forecast of 257.55 USD and a high forecast of 359.1 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
53%

For the last 12 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 35%. The projected CAGR for the next 3 years is 53%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett